Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Helix Biopharma Corp. (HBPCF : OTC)
 
 • Company Description   
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Its primary drug candidate is L-DOS47, which is intended for the treatment of inoperable, locally advanced, recurrent, or metastatic non-small cell lung cancer. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. It's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.18 Daily Weekly Monthly
20 Day Moving Average: 0 shares
Shares Outstanding: 158.03 (millions)
Market Capitalization: $28.19 (millions)
Beta: -0.19
52 Week High: $0.81
52 Week Low: $0.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.00% 9.16%
12 Week -28.64% -22.88%
Year To Date -28.64% -15.48%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9120 Leslie Street Suite 205
-
Richmond Hill,A6 L4B 3J9
CAN
ph: 905-841-2300
fax: 905-841-2244
ir@helixbiopharma.com http://www.helixbiopharma.com
 
 • General Corporate Information   
Officers
Heman Chao - Chief Executive and Director
Slawomir Majewsk - Chairman
Frank Michalargias - Chief Financial Officer
Robert Gillies - Director
Ireneusz Fafara - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 422910109
SIC: 2834
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/13/22
Share - Related Items
Shares Outstanding: 158.03
Most Recent Split Date: (:1)
Beta: -0.19
Market Capitalization: $28.19 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/13/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
04/30/22 - -
01/31/22 - -
10/31/21 - -4,094.72
ROA
04/30/22 - -
01/31/22 - -357.90
10/31/21 - -253.52
Current Ratio
04/30/22 - -
01/31/22 - 0.22
10/31/21 - 0.60
Quick Ratio
04/30/22 - -
01/31/22 - 0.22
10/31/21 - 0.60
Operating Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Net Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Pre-Tax Margin
04/30/22 - -
01/31/22 - -
10/31/21 - -
Book Value
04/30/22 - -
01/31/22 - -0.02
10/31/21 - -0.02
Inventory Turnover
04/30/22 - -
01/31/22 - -
10/31/21 - -
Debt-to-Equity
04/30/22 - -
01/31/22 - -
10/31/21 - -
Debt-to-Capital
04/30/22 - -
01/31/22 - -
10/31/21 - -
 

Powered by Zacks Investment Research ©